drugset
drugset / Trial / NCT05529069

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069 ↗

Phase 2 Recruiting 30 enrolled M.D. Anderson Cancer Center Loxo Oncology, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).

Timeline

Start
2023-01-25
Primary completion
2027-04-28
Completion
2027-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirtobrutinib Other / unclassified — Oral
Subject Venetoclax Small molecule — Oral

Indications

mantle cell lymphoma